Gandhi Maher K, Marcus Robert E
Department of Haematology, Princess Alexandra Hospital, Brisbane, 4006 QLD, Australia.
Blood Rev. 2005 May;19(3):165-78. doi: 10.1016/j.blre.2004.09.001.
Follicular lymphoma (FL) is a malignancy of follicle centre B cells that have at least a partially follicular pattern, and is the commonest type of indolent Non-Hodgkin's lymphoma. Except in the subset of patients with localized disease, FL should still be regarded as an incurable malignancy with a relentless relapsing/remitting course. However, the provocative new data covered by this review (including anti-CD20 antibody therapy, BCL-2, radioimmunotherapy, new chemotherapeutic agents and anti-idiotype vaccination), provides much cause for excitement and guarded optimism. Rituximab represents a novel treatment approach for a variety of disease settings, with a proven excellent efficacy and toxicity profile. Long-term data is required to establish whether its use translates into survival benefit. As the clinical activity of rituximab and other new therapeutic approaches becomes established, it will be important to determine how best to integrate these results into the standard care of patients with follicular lymphoma.
滤泡性淋巴瘤（FL）是一种起源于滤泡中心B细胞的恶性肿瘤，至少具有部分滤泡样结构，是最常见的惰性非霍奇金淋巴瘤类型。除局限性疾病患者亚组外，FL仍应被视为一种无法治愈的恶性肿瘤，具有持续复发/缓解的病程。然而，本综述涵盖的令人振奋的新数据（包括抗CD20抗体治疗、BCL-2、放射免疫治疗、新型化疗药物和抗独特型疫苗接种），让人充满兴奋并抱有谨慎的乐观态度。利妥昔单抗代表了一种适用于多种疾病情况的新型治疗方法，已证实具有出色的疗效和毒性特征。需要长期数据来确定其使用是否能转化为生存获益。随着利妥昔单抗和其他新治疗方法的临床活性得到确立，确定如何最好地将这些结果整合到滤泡性淋巴瘤患者的标准治疗中将变得至关重要。
